Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SPRB Spruce Biosciences, Inc.

Closed 01-15 16:00:00 EST

74.89

-3.48

-4.44%

盘后74.89

+0.000.00%

16:47 EST

High78.20	Low74.81	Vol12.57K
Open75.85	D1 Closing78.37	Amplitude4.32%
Mkt Cap79.81M	Tradable Cap65.70M	Total Shares1.07M
T/O959.70K	T/O Rate1.43%	Tradable Shares877.30K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SPRB","market":"US","secType":"STK","nameCN":"Spruce Biosciences, Inc.","latestPrice":74.89,"timestamp":1768510800000,"preClose":78.37,"halted":0,"volume":12572,"hourTrading":{"tag":"盘后","latestPrice":74.89,"preClose":74.89,"latestTime":"16:47 EST","volume":62,"amount":4654.01,"timestamp":1768513678540},"delay":0,"floatShares":877301,"shares":1065700,"eps":-82.47875,"marketStatus":"Closed","change":-3.48,"latestTime":"01-15 16:00:00 EST","open":75.85,"high":78.1995,"low":74.8119,"amount":959703.553,"amplitude":0.043226,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-82.47875,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768554000000},"marketStatusCode":5,"adr":0,"listingDate":1602216000000,"exchange":"NASDAQ","adjPreClose":78.37,"preHourTrading":{"tag":"盘前","latestPrice":75.54,"preClose":78.37,"latestTime":"09:28 EST","volume":52,"amount":3939.30004,"timestamp":1768487293996},"postHourTrading":{"tag":"盘后","latestPrice":74.89,"preClose":74.89,"latestTime":"16:47 EST","volume":62,"amount":4654.01,"timestamp":1768513678540},"volumeRatio":0.322055,"impliedVol":0.883,"impliedVolPercentile":0.7857},"requestUrl":"/m/hq/s/SPRB/tweets","defaultTab":"tweets","newsList":[{"id":"2601362581","title":"BRIEF-Spruce Biosciences Secures Up To $50 Million In Growth Capital From Avenue Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2601362581","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601362581?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:23","pubTimestamp":1767878630,"startTime":"0","endTime":"0","summary":"BRIEF-Spruce Biosciences Secures Up To $50 Million In Growth Capital From Avenue CapitalJan 8 (Reuters) - Spruce Biosciences Inc SPRB.O:SPRUCE BIOSCIENCES SECURES UP TO $50 MILLION IN GROWTH CAPITAL F","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA80HMRL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"gpt_icon":0},{"id":"2601364521","title":"Spruce Biosciences Secures $50 Million Loan Facility from Avenue Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2601364521","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601364521?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:02","pubTimestamp":1767877335,"startTime":"0","endTime":"0","summary":"Spruce Biosciences, Inc., a late-stage biopharmaceutical company focused on therapies for neurological disorders, has entered into a new loan facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group. The agreement provides Spruce with up to $50 million in growth capital, including an initial $15 million tranche to be funded around January 9, 2026. The remaining $35 million is available in additional tranches, subject to the achievement of key regulatory and commercial milestones related to the development and planned commercial launch of tralesinidase alfa enzyme replacement therapy  for Sanfilippo Syndrome Type B . The loan has a 42-month term and is aimed at supporting the company’s operations, regulatory filings, and pre-launch commercial activities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inf","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL8MHH80:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"gpt_icon":0},{"id":"2601364375","title":"Spruce Biosciences Inc - Initial Funding of $15 Mln Extends Cash Runway Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2601364375","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601364375?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:00","pubTimestamp":1767877206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA80HMRL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"gpt_icon":0},{"id":"2601036482","title":"Spruce Biosciences Secures up to $50 Million in Growth Capital From Avenue Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2601036482","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601036482?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:00","pubTimestamp":1767877206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA80HMRL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRB","BK4139"],"gpt_icon":0},{"id":"2593549007","title":"BUZZ-Oppenheimer starts Spruce Biosciences with \"outperform\" rating on rare disease strength","url":"https://stock-news.laohu8.com/highlight/detail?id=2593549007","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593549007?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:12","pubTimestamp":1766495535,"startTime":"0","endTime":"0","summary":"BUZZ-Oppenheimer starts Spruce Biosciences with \"outperform\" rating on rare disease strength** Oppenheimer initiates coverage on Spruce Biosciences SPRB.O with \"outperform\" rating and $283 PT** PT imp","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nL6N3XT0KV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","BMRN","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","BK4139","BK4566","IE0002270589.USD","SPRB"],"gpt_icon":0},{"id":"2593148468","title":"Spruce Biosciences Coverage Assumed by HC Wainwright & Co. at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2593148468","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593148468?lang=en_us&edition=fundamental","pubTime":"2025-12-22 19:41","pubTimestamp":1766403660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPRB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 22, 2025 06:41 ET (11:41 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"gpt_icon":0},{"id":"2593481457","title":"Refile-Spruce Biosciences, Inc. : H.c. Wainwright Assumes Coverage With Buy Rating and Target Price $220 (Clarifies to Say Assumes Coverage)","url":"https://stock-news.laohu8.com/highlight/detail?id=2593481457","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593481457?lang=en_us&edition=fundamental","pubTime":"2025-12-22 19:21","pubTimestamp":1766402489,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nL4N3XS0M5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRB","BK4139"],"gpt_icon":0},{"id":"2593481359","title":"Spruce Biosciences, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating  and Target Price $220","url":"https://stock-news.laohu8.com/highlight/detail?id=2593481359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593481359?lang=en_us&edition=fundamental","pubTime":"2025-12-22 19:09","pubTimestamp":1766401760,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nAZN4RI2ZN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"gpt_icon":0},{"id":"2591124649","title":"Spruce Biosciences Sets New Director Compensation Terms with Stock Options and Retainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2591124649","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591124649?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:06","pubTimestamp":1765803961,"startTime":"0","endTime":"0","summary":"Spruce Biosciences Inc. has appointed Keli Walbert to its board of directors, effective immediately. As part of the company's non-employee director compensation policy, Walbert has been granted a nonstatutory stock option to purchase 3,400 shares of common stock, vesting monthly over three years. She will receive an annual cash retainer of $40,000 for her role as director and $5,000 for serving on the Compensation Committee, both pro-rated for 2025. Starting January 1, 2026, the Compensation Committee retainer will increase to $5,500. From the 2026 Annual Meeting, Walbert will also be eligible for an annual stock option to purchase 1,700 shares, vesting by the next annual meeting or one year from grant, whichever comes first.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDLsmvlw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"gpt_icon":0},{"id":"2591649994","title":"Spruce Biosciences Appoints Keli Walbert to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649994","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591649994?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:01","pubTimestamp":1765803675,"startTime":"0","endTime":"0","summary":"Spruce Biosciences Inc. has appointed Keli Walbert to its Board of Directors. Walbert brings over 20 years of commercial leadership experience in the pharmaceutical industry, including her recent role as Executive Vice President, U.S. Commercial, at Horizon Therapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire  on December 15, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL37BWxx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","IE00BJT1NW94.SGD","LU1571399168.USD","BK4599","LU2468319806.SGD","BK4585","SPRB","IE00B4R5TH58.HKD","LU1023059063.AUD","LU1057294990.SGD","LU0868494617.USD","BK4139","BK4566","LU1983299246.USD","LU2089984988.USD","LU1061106388.HKD","SG9999001440.SGD","LU0889565916.HKD","LU2242646821.SGD","LU0109394709.USD","IE00BJJMRZ35.SGD","BK4588","AMGN","LU0122379950.USD","LU2112291526.USD","LU0320765992.SGD","IE00BFTCPJ56.SGD","BK4581","LU0289739699.SGD","IE0009355771.USD","BK4534","IE0002141913.USD","LU2242652126.USD","IE00B2B36J28.USD","LU0058720904.USD"],"gpt_icon":0},{"id":"2591649661","title":"Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649661","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591649661?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:00","pubTimestamp":1765803606,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUAQKR4C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"gpt_icon":0},{"id":"2591689054","title":"Spruce Biosciences Reprices Stock Options to Boost Employee Retention","url":"https://stock-news.laohu8.com/highlight/detail?id=2591689054","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591689054?lang=en_us&edition=fundamental","pubTime":"2025-12-13 05:04","pubTimestamp":1765573468,"startTime":"0","endTime":"0","summary":"Spruce Biosciences Inc. has approved a stock option repricing plan, effective December 11, 2025. Under this plan, the exercise price of certain outstanding stock options held by employees and directors, including executive officers, has been reduced to the market price of the company's common stock as of the effective date. The repriced options will only become exercisable at the reduced price after a designated retention period, which lasts up to twelve months, until FDA approval of the company's tralesinidase alfa product candidate, or a change in control, whichever occurs first. The repriced options include 11,666 options for CEO Javier Szwarcberg and 6,131 options for CFO Samir Gharib.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL5hF7mk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"gpt_icon":0},{"id":"2588296120","title":"Spruce Biosciences Shares Rise After Upgrade From Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2588296120","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588296120?lang=en_us&edition=fundamental","pubTime":"2025-12-04 04:00","pubTimestamp":1764792058,"startTime":"0","endTime":"0","summary":"Spruce Biosciences  shares were up more than 7% in recent Wednesday trading after Leerink upgraded the biopharmaceutical company's stock to outperform from market perform, with a price target of $160.Trading volume stood at about 128,000 shares compared with a daily average of about 562,000.Price: 95.92, Change: +6.72, Percent Change: +7.53","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPRB"],"gpt_icon":0},{"id":"2588257041","title":"Spruce Biosciences Raised to Outperform From Market Perform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2588257041","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588257041?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:53","pubTimestamp":1764769980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPRB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2025 08:53 ET (13:53 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB"],"gpt_icon":0},{"id":"2588904815","title":"Leerink Upgrades Spruce Biosciences to Outperform From Market Perform, Price Target is $160","url":"https://stock-news.laohu8.com/highlight/detail?id=2588904815","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588904815?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:27","pubTimestamp":1764761279,"startTime":"0","endTime":"0","summary":"Leerink Upgrades Spruce Biosciences to Outperform From Market Perform, Price Target is $160","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPRB"],"gpt_icon":0},{"id":"2588900048","title":"Spruce Biosciences Shares Add 2.6% Premarket After Leerink Partners Upgrades Rating to 'Outperform' From 'Market Perform'","url":"https://stock-news.laohu8.com/highlight/detail?id=2588900048","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588900048?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:24","pubTimestamp":1764761080,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nL4N3X90T6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRB","BK4139"],"gpt_icon":0},{"id":"2583682607","title":"Top News Today: Stocks Mixed as AI Selloff Slows","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682607","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682607?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:45","pubTimestamp":1763156700,"startTime":"0","endTime":"0","summary":"TREASURYS: Treasury yields rose amid doubts about the Federal Reserve's next move.COMMODITIES: Oil futures rose after Ukraine drone attacks on a Russian Black Sea port.Walmart picked one of its longtime executives, John Furner, to become its next chief executive, preserving its tradition of promoting an insider to steer the nation's biggest retailer. The 51-year-old Furner was seen inside the company as the likely heir apparent and ready for his next step after six years leading Walmart's U.S. business. Outside the company, the Walmart veteran-and son of a Walmart executive-was seen as a potential CEO candidate for other firms too.The reopened federal government will on Thursday release the first backlogged monthly jobs report, for the month of September. And a flood of other data is due to start flowing soon.They promised investments in the U.S. that would reduce Switzerland's trade imbalance with the U.S., according to people familiar wit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","LITS","LU2468319806.SGD","SPRB","LU0861579265.USD","LWLG","NWBO","BK4007","LFMD","BK4152","MRK","TVGN","LU2592432038.USD","LU2023250843.SGD","GPUS","LU2361044865.SGD","IPAR","PNBK","ASPI","WMT","ALTS","OTLC","LU2750360641.GBP","LU2430703251.USD","SRG","ELDN","LU1066053197.SGD","UAVS","BYFC","PRPO","HP","BK4561","KALA","IIIV","TORM","LU0203347892.USD","BRC","XP","LU1974910355.USD","ARMK","LU0061474960.USD","LU2430703178.SGD","ALBT","RHEP","JJSF","STI","LU1430594728.SGD","IE00B2B36J28.USD","AAME"],"gpt_icon":0},{"id":"2582362303","title":"Spruce Biosciences Is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2582362303","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582362303?lang=en_us&edition=fundamental","pubTime":"2025-11-11 22:05","pubTimestamp":1762869900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPRB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2025 09:05 ET (14:05 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB"],"gpt_icon":0},{"id":"2582368566","title":"Spruce Biosciences price target raised to $259 from $254 at Citizens JMP","url":"https://stock-news.laohu8.com/highlight/detail?id=2582368566","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582368566?lang=en_us&edition=fundamental","pubTime":"2025-11-11 18:55","pubTimestamp":1762858510,"startTime":"0","endTime":"0","summary":"Citizens JMP raised the firm’s price target on Spruce Biosciences (SPRB) to $259 from $254 and keeps an Outperform rating on the shares. Spruce rem...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spruce-biosciences-price-target-raised-to-259-from-254-at-citizens-jmp-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spruce-biosciences-price-target-raised-to-259-from-254-at-citizens-jmp-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JMP","SPRB"],"gpt_icon":0},{"id":"2582800232","title":"Spruce Biosciences Q3 net loss narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2582800232","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582800232?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:13","pubTimestamp":1762809227,"startTime":"0","endTime":"0","summary":"Spruce Biosciences Q3 net loss narrowsOverviewSpruce Biosciences reports Q3 net loss of $8.2 mln, with reduced operating expensesCompany secured $50 mln in private placement financing from healthcare ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM122:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sprucebiosciences.com","stockEarnings":[{"period":"1week","weight":0.0036},{"period":"1month","weight":-0.0285},{"period":"3month","weight":-0.4996},{"period":"6month","weight":711.4545},{"period":"1year","weight":210.0124},{"period":"ytd","weight":-0.1003}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0141},{"period":"3month","weight":0.045},{"period":"6month","weight":0.1},{"period":"1year","weight":0.1858},{"period":"ytd","weight":0.0124}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.192014},{"month":2,"riseRate":0.6,"avgChangeRate":0.014969},{"month":3,"riseRate":0,"avgChangeRate":-0.288755},{"month":4,"riseRate":0,"avgChangeRate":-0.208561},{"month":5,"riseRate":0.4,"avgChangeRate":-0.03765},{"month":6,"riseRate":0.4,"avgChangeRate":-0.079875},{"month":7,"riseRate":0.6,"avgChangeRate":0.089441},{"month":8,"riseRate":0.4,"avgChangeRate":0.028537},{"month":9,"riseRate":0.4,"avgChangeRate":-0.136102},{"month":10,"riseRate":0.4,"avgChangeRate":2.105377},{"month":11,"riseRate":0.5,"avgChangeRate":0.001192},{"month":12,"riseRate":0.333333,"avgChangeRate":0.217863}],"exchange":"NASDAQ","name":"Spruce Biosciences, Inc.","nameEN":"Spruce Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Spruce Biosciences, Inc.(SPRB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Spruce Biosciences, Inc.,SPRB,Spruce Biosciences, Inc.股票,Spruce Biosciences, Inc.股票老虎,Spruce Biosciences, Inc.股票老虎国际,Spruce Biosciences, Inc.行情,Spruce Biosciences, Inc.股票行情,Spruce Biosciences, Inc.股价,Spruce Biosciences, Inc.股市,Spruce Biosciences, Inc.股票价格,Spruce Biosciences, Inc.股票交易,Spruce Biosciences, Inc.股票购买,Spruce Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Spruce Biosciences, Inc.(SPRB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction